MAGP-2: An Extracellular Factor Shown to have Pro-Angiogenic Properties in vivo Download HRPP SOPs Clinical Trials Find a Researcher NJH ID: 06-05 Background Excessive angiogenesis has emerged as an essential feature of tumor development and appears to be regulated in part by extracellular matrix proteins. Scientists at National Jewish Health have identified an extracellular matrix protein (designated MAGP-2) that acts as a pro-angiogenic agent in vivo. Potential Applications A target for inhibiting angiogenesis in cancer and other angiogenesis-dependent diseases Stimulating neovascularization by administration of MAGP-2 to ischemic tissues in coronary artery disease, stroke, and delayed wound healing A diagnostic biomarker, especially for cancer Advantages of Invention Because of its extracellular nature, MAGP-2 can be easily detectable and targetable by antibody-based technologies for example. State of Development Our scientists have shown the following: In vitro: MAGP-2 is over expressed in human uterine tumor samples and has been associated with ovarian and head & neck cancer Endothelial cell expression of MAGP-2 increases during angiogenesis in vitro MAGP-2 stimulates angiogenic sprouting in 3-dimensional collagen cultures MAGP-2 increases endothelial cell proliferation and invasion in vitro In vivo: Significant enhancement of neovascularization when MAGP-2 was implanted into mice through matrigel plugs MAGP-2 increases tumor size and angiogenesis in mice Publications Albig, AR. et al. Angiogenesis 10.3 (2007): 197-216. PMID: 17632767. Albig, AR. et al. Microvascular Research 76.1 (2008): 7-14. PMID: 18417156. Leung, CS. et al. Nature Communications 5 (n.d.): n. pag. PMID: 25277212 Spivey, KA. et al. Cell Adhesion and Migration 4.2 (n.d.): 169-71. PMID: 20400864. Inventors William P. Schiemann, PhD and Allan Albig, PhD Patent Status U.S. Patents #9,505,819, #8,629,107 and #8,158,107. Other U.S. Patents Pending. Licensing Status This technology is available for licensing. For Further Information, Contact: Emmanuel Hilaire, PhD Director Technology Transfer Office National Jewish Health 1400 Jackson Street, Room M206b Denver, CO 80206 Voice: 303.398.1262 Fax: 303.270.2352 HilaireE@njhealth.org